For personal use only

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Friday December 03, 2021

The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

Refer to next page for full details of the announcement

For personal use only

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1. The announcement is New announcement
2. Date of this announcement

3/12/2021

For personal use only

2.1 The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

For personal use only

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

MYXAN : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

3/12/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes

Provide details of the KMP or +associates being issued +securities.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

• Rights are eligible for vesting over a period of up to five years from the date of the grant, subject to achievement of specific vesting condition hurdles.
• 20% of the grant eligible for vesting 1 year after the base test date, 30% eligible for vesting 2 years after the base test date and the balance eligible for vesting 3 years after the base test date, subject to achievement of the vesting conditions.
• The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%.
• If CAGR performance conditions are met, vesting occurs progressively and at continuously increasing hurdles.
• For further information refer to the 2021 Annual Report - https://www.maynepharma.com/investor-relations/results-reports/

Any other information the entity wishes to provide about the +securities the subject of this notification

• The base test date for Rights is set as 1 September 2021 and the expiry date is 30 September 2026
• The Base Test Price for the Rights is $0.33.
• If the Rights are not exercised before the expiry date they will automatically lapse.
• There are no voting rights or rights to dividends whilst the participant holds a Right.